XaMINA: A Real-World, Prospective, Observational Study of Treatment-Na ïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia

CONCLUSION: XaMINA demonstrated low incidence rates of major bleeding events and thromboembolic events in patients with NVAF newly initiating rivaroxaban in South Korea and Taiwan, consistent with previous real-world studies reconfirming the results of the ROCKET AF study.TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov (identifier NCT03284762) on 15 September 2017.PMID:35616848 | DOI:10.1007/s12325-022-02102-8

Source: Adv Data - May 26, 2022 Category: Epidemiology Authors: Ping-Yen Liu Eue-Keun Choi Tae-Seok Kim Jen-Yuan Kuo Jung Myung Lee Young Keun On Sang-Weon Park Hyung-Wook Park Dong-Gu Shin Lili Wang Hsueh-Wei Yen Moon-Hyoung Lee XaMINA Investigators Source Type: research